Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662282 · ClinicalTrials.gov registry record · Phase 3
Omegaven as Alternative Parenteral Fat Nutrition
A Phase 3 study, sponsored by University of South Florida.
- Completed
- Registry status
- Phase 3
- Development phase
- 2
- Enrollment target
NCT03662282: Completed Phase 3 study, sponsored by University of South Florida.
NCT03662282 is a Phase 3 study that has completed, run by University of South Florida. The registered enrollment target is 2 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03662282, a Phase 3 study, has completed, sponsored by University of South Florida.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2 participants
- Enrollment target
Study Summary
To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis
Primary Outcome
Number of participant with decrease in direct bilirubin levels within 30 days of treatment
Interventions
- DRUG Omegaven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2019-01-07 |
| Phase | Phase 3 |
What the finished NCT03662282 record still lists
NCT03662282 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Omegaven is the first listed.
NCT03662282 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03662282 about?
NCT03662282 is a clinical study titled "Omegaven as Alternative Parenteral Fat Nutrition". To provide Omegaven® as a compassionate treatment for critically ill infants with parenteral nutrition associated cholestasis
What is the current status of trial NCT03662282?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2 participants. The study started on 2018-10-23. Estimated completion is 2019-01-07.
What interventions are being tested in trial NCT03662282?
The interventions under investigation include: Omegaven (DRUG).
Who is sponsoring clinical trial NCT03662282?
This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03662282's enrollment target sits among peer trials
2 2000th of 2000 the lowest of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI